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Abstract
Background: To demonstrate clinical characteristics of adrenal incidentaloma in South China and explore its
comprehensive management.
Methods: The clinical data of patients with adrenal neoplasm from Jan 1998 to Dec 2012 were retrospectively
analysed. Patients with suspicion of adrenal abnormalities or those in whom adrenal abnormalities were detected
in the staging procedures of other cancers were excluded. Most patients with adrenal incidentaloma chose to
have adrenalectomy, and some chose surveillance. The relationships between clinical features were analysed with
a chi-square test and rank sum test.
Results: In total, 634 patients with adrenal incidentaloma were studied. Their age ranged from 17 to 85 years old
with a median age of 50 years. Of 478 cases with pathological results, adenoma was the most common tumour
(233/478), with 84 cases of pheochromocytoma and 36 cases of adrenocortical carcinoma were 84 and 36. When
the tumour size was ≤4 cm, >95 % were benign; when the tumour size was >6 cm, 33 % were malignant. For patients
with a tumour size ≤4 cm, 249/376 cases had an adrenalectomy performed. Due to anxiety over a potential malignant
transformation and enlargement, most patients (>80 %) under surveillance preferred to undergo adrenalectomy.
Conclusions: Pheochromocytoma and adrenocortical carcinoma were not rare tumours of adrenal incidentaloma, and
4 cm is a good size cutoff to use in the diagnosis of an adrenal incidentaloma. Other than surveillance, laparoscopic
adrenalectomy may become the method of choice for management of small adrenal incidentaloma.
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Background
As imaging techniques evolve, the incidence of adrenal
incidentaloma is increasing. The reported incidence of
adrenal incidentaloma in an autopsy series is 2.1–8.7 %,
which was shown to increase with age [1, 2]. However,
the diagnosis of adrenal incidentaloma is not often made
during a general health screening. Moreover, given the
various types of adrenal neoplasm, there are challenges
in the management of adrenal incidentaloma.
As laparoscopic adrenalectomy becomes popular, the
rate of surgery is increasing for adrenal incidentalomas
[3]. For instance, adrenalectomy is recommended for
subclinical Cushing’s syndrome, which is related to long-
term metabolic disorders [4]. However, approximately
80 % of adrenal incidentalomas are benign and non-
hypersecreting. In most reports, nonfunctioning adenoma
is the most common tumour, but adrenocortical carcinoma
(ACC) plays an important role in some medical centres
[3, 5]. In addition, the evaluation of malignant lesions is
uncertain, and patients under surveillance suffer psy-
chological burden. Therefore, surgery or a more conser-
vative approach is controversial for adrenal incidentaloma
in clinical practice.
In 2002 and 2009, the NIH and AACE/AAES, re-
spectively, published clinical practice guidelines for in-
cidentaloma, recommending follow-ups for patients
with small tumours (<4 cm) without malignant charac-
teristics or hormonal activity [6, 7]. However, the
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multidisciplinary management of adrenal incidentalo-
mas was not diligently performed as guidelines recom-
mended, and several patients were not evaluated by
endocrinologists nor did they have an endocrine examin-
ation [8]. This study retrospectively analysed the clinical
characteristics and management of patients with adrenal
incidentalomas, who were referred to the First Affiliated
Hospital of Sun Yat-sen University from 1998 to 2012. In
South China, this hospital is the largest medical centre
with sophisticated endocrinologists and urologists, thus,




The clinical data of patients with adrenal neoplasm from
Jan 1998 to Dec 2012 were retrospectively analysed. Pa-
tients with suspicions of adrenal abnormalities or those in
whom adrenal abnormalities were detected during staging
procedures of other cancers were excluded. The pathology
results and clinical data, including age, presentation, endo-
crine examination, images and treatment, were retrieved
and recorded by an experienced pathologist.
Treatment
Biochemical evaluations were performed in most patients
with an adrenal mass. The first laparoscopic adrenalec-
tomy for adrenal incidentaloma was performed in August
1998; then, for patients with a tumour ≤4 cm, surveillance
or laparoscopic adrenalectomy was suggested. For patients
with a suspected malignant tumour (enhancement >10
HU or heterogeneous) or with a tumour size >4 cm, open
adrenalectomy was considered. For patients in whom
there were differing opinions about appropriate man-
agement, treatment approaches were not performed ac-
cording to the guidelines.
Statistical analysis
Using SPSS 16.0 Package (SPSS, Inc., Chicago, IL), rela-
tionships between clinical features, treatment approach
and pathological result (malignant or benign) were ana-
lysed with the chi-square test and rank sum test; P < 0.05
was considered to be significant.
Results
Clinical characteristics
During 1998 and 2012, 877 patients with adrenal neo-
plasm were treated in the First Affiliated Hospital of Sun
Yat-sen University, and 634 of them had adrenal inciden-
talomas. Their age ranged from 17 to 85 years old with a
median age of 50 years. Of these, 293 were male, and
341 were female. Then, 138 were followed by surveillance
with a median time of 8 months (3–96 months), while an
enlargement of the tumour (>1 cm per year or >4 cm) or
hormone transformation was detected in 118 patients
who chose adrenalectomy. The other 20 patients still pre-
ferred surveillance, though 2 of them had tumours that
transformed to Cushing syndrome, 1 transformed to
pheochromocytoma, and 2 had tumours >4 cm in size
(Additional file 1).
Endocrinologic and pathologic results
With the combination of endocrinologists and urolo-
gists, hormonal examination was regularly administered
in 529 patients. Of these patients, 69 cases were diag-
nosed as having pheochromocytoma, 16 with hypercorti-
solism, 6 with subclinical Cushing syndrome, 13 with
aldosteronism, 1 with adrenocortical hypersecretion, and
424 with having a nonfunctional tumour. Pathologic
diagnosis was available in 478 patients, and details are
listed in Tables 1 and 2.
Following a preoperative endocrine examination, of
233 patients with cortical adenoma, 15 cases were diag-
nosed as having pheochromocytoma, 10 had hypercorti-
solism, and 5 had subclinical Cushing syndrome. Of 84
patients with pheochromocytoma (malignant and benign),
48 cases were diagnosed as pheochromocytoma, 1 with
aldosteronism, and the others were nonfunctioning.
History of tumour
In patients with pathologic results, there were 63 pa-
tients with a history of benign tumour and 24 with a his-
tory of cancer. In these patients with a history of benign
tumour, 15 patients had a history of a thyroid tumour,
15 had a history of a hysteromyoma, and 3 had a history
of two benign tumours. Of these 63 patients, 4 had adre-
nocortical carcinoma, and 5 had pheochromocytoma. In
patients with a history of cancer, 17 of them had a benign
adenoma, 2 had pheochromocytoma, 1 had adrenocortical
Table 1 Clinical characters of patients without pathological results
No. Gender Age (year) Size (cm) Clinical type
Male: Female Median (range) Median (range) Benign: Malignant
Hormone active 9 5:4 51 (32–75) 7.8 (1.1–15) 3:6
Non-function 104 54:50 55 (25–85) 2 (1.0–14) 92:12
Undefined 43 24:19 62 (31–80) 2.2 (1.0–14) 39:4
Total 156 83:73 56 (25–85) 2.1 (1.0–15) 134:22
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carcinoma, and 4 had metastasis, including 2 from the
liver, 1 from a kidney and 1 from the colon.
For patients without a history of any tumour, 31 had
adrenocortical carcinoma, 9 had malignant pheochromo-
cytoma, 1 had metastasis whose primary lung cancer
was detected after adrenalectomy, and 6 others were ma-
lignant. Of these benign tumours, 67 were diagnosed as
pheochromocytoma.
Tumour size and type
Tumour size was related to its type. In this study, for a
tumour size >4 cm or ≤4 cm, the proportion of having a
malignant tumour was 56/229 and 1/249, respectively
(P < 0.001). For a tumour size >6 cm or ≤6 cm, the pro-
portion of having a malignant tumour was 48/144 and
9/334, respectively (P < 0.001).
Using data from patients with pathologic results, a ROC
curve was performed, and the cut-off size was 5.4 cm, and
the AUC was 0.877 (95 % confidential intervals: 0.84–
0.913) with a sensitivity of 93 % and a specificity of 71 %
(as shown in Fig. 1). For tumour size >5.4 cm or ≤5.4 cm,
the proportion of having a malignant tumour was 53/302
and 4/176, respectively (P < 0.001).
Treatment approaches
Of these 634 patients, 470 had surgery performed, in-
cluding 228 cases of open surgery and 242 of laparo-
scopic adrenalectomy, and 8 patients had fine-needle
biopsy performed; the other 156 patients chose conserva-
tive treatment. The relationships between treatment ap-
proach and clinical characteristics are shown in Table 3,
and the tumour size of patients who chose laparoscopic
adrenalectomy or surveillance was smaller than patients
who had open adrenalectomy performed (P < 0.001). In
all, of 376 patients with a tumour size ≤4 cm, 249 chose
adrenalectomy, including 186 cases of nonfunctioning tu-
mours and 23 patients without biochemical evaluation. Of
258 patients with a tumour size >4 cm, 29 refused adre-
nalectomy, including 8 patients with multi-organ metasta-
sis. For patients who chose conservative treatment, 40/85
patients >55 years were advised to have surveillance for
their comorbidities, which included chronic obstructive
pulmonary disease, chronic renal failure, severe pneu-
monia,diabetes with multi-organ involvement,coronary
heart disease,hepatocirrhosis with ascitic fluid and se-
vere malnutrition.
Discussions
As popular as abdominal imaging examination has be-
come, adrenal incidentaloma has now become a com-
mon finding in clinical practice. Although most cases
are benign and nonfunctioning, the presence of an ad-
renal incidentaloma are still critically concerning for pa-
tients and physicians alike because of the risk of
transition to malignancy or hormonal hyperfunction. In
most reports, malignant and functional lesions repre-
sented a small part of adrenal incidentalomas, but some
medical centres demonstrated that adrenal adenocarcin-
oma and pheochromocytoma accounted for 12 % (47/380)
and 11 % (42/380), respectively [5]. During a long-term
follow-up, the 2-year and 5-year risk of tumour growth
and hormonal alteration for adrenal incidentalomas was
29 % and 47 %, respectively [9]. In this study, malignance
and pheochromocytoma represented 27.6 % of all patients
with pathologic results. Of patients under surveillance,
more than 80 % (123/138) had to receive an operation.
Meanwhile, several reports recently revealed that for pa-
tients with adrenal incidentaloma and subclinical Cushing
syndrome, adrenalectomy led to a better outcome than
conservative treatment in terms of reducing hypertension
Table 2 Clinical characters of patients with pathological results
No. Gender Age (year) Size (cm) Operation
Male: Female Median (range) Median (range) Laparoscopic: Open
Malignant pheochromocytoma 9 5:4 47 (27–72) 6 (4.7–8.5) 2:7
Adrenocortical carcinoma 36 17:19 49 (25–77) 9.5 (3.0–17.5) 6b:30
Metastasis 5 4:1 59 (53–62) 7.5 (5.0–8) 1a:4
Other malignant 7 2:5 41 (20–77) 2.8 (1.0–18) 147:86
Myelolipoma 24 9:15 54 (22–75) 4.5 (1.5–12) 15a:9
Ganglioneuroma 22 15:7 37 (21–63) 5.5 (1.1–12) 8:14
Pheochromocytoma 75 39:36 47 (21–77) 5.5 (1.2–23) 23:52
Cyst 32 11:21 37 (22–64) 6 (2.0–18) 25:7
Nodular hyperplasia 12 4:8 43 (36–65) 2 (1.1–3) 11:1
Other benign 23 8:15 40 (21–68) 5.4 (2.0–13.5) 11:12
Total 478 212:266 48 (17–77) 4 (1.0–23) 250:228
aIncluding 1 patient performed fine-needle biopsy other than dissection
bAll patients performed fine-needle biopsy other than dissection
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and metabolic disorders [10–14]. Therefore, adrenalectomy
was recommended to patients with potential of having hor-
monal alteration or malignant transformation.
As reported, a 4 cm cutoff was associated with a sensi-
tivity of 93 % and a specificity of 24 % in preoperative
diagnosis [15]. Additionally, 4.75 cm was reported to be a
cutoff with a sensitivity of 90 % and a specificity of 58 % in
a minor population [16]. Our cutoff analysis demonstrated
that 5.4 cm was a comparable cutoff size with a sensitivity
of 93 % and a specificity of 71 %, respectively. Meanwhile,
the sensitivity and specificity for cutoffs of 4 cm, were
98 % and 59 %, respectively. In our opinion, for the poten-
tial consequences of a misdiagnosis of a malignant tumour,
a high sensitivity was preferred. Therefore, we confirmed
that 4 cm was a good cutoff, as only 1 tumour size ≤4 cm
was malignant in this study. Occasionally, small adrenal
cancers were reported, and in this study, the smallest ma-
lignant tumour was 3 cm in size.
For patients with pathologic pheochromocytoma, a
preoperative evaluation revealed that approximately
43 % patients with pheochromocytoma were not diag-
nosed before their operations, which was similar to
other reports [15, 17]. Therefore, before adrenalectomy
for adrenal incidentaloma, anaesthesiology preparation
for pheochromocytoma should be performed carefully.
Also, 10/19 patients with a tumour ≤4 cm had laparo-
scopic adrenalectomy performed, and 1 patient was trans-
formed to an open approach due to severe hypertension.
As reported, regular preoperative workup could reduce
perioperative morbidities [18].
Fig. 1 ROC curve of tumour size and tumour type
Table 3 Relationships between treatment approach and clinical characters
No. Gender Age (year) Size (cm) Tumor type
Male: Female Median (range) Median (range) Benign: Malignant
Laparoscopic 242 101:141 52 (20–75) 3 (1.0–18) 239:3
Open 228 102:126 47 (17–77) 6 (1.0–23) 181:47
Surveillance 156 83:73 56 (25–85) 2.1 (1.0–15) 134:22a
Biopsy 8 7:1 51 (26–61) 8.5 (7.0–12) 1:7
Total 634 293:341 50 (17–85) 3.2 (1.0–23) 555:79
aClinical tumor type
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For patients with adrenocortical carcinoma, 7 had me-
tastasis, and 1 had a malignant embolus. The median
size was 9.5 cm with range from 3 to 17.5 cm, which
was larger than benign tumours (9.5 vs 3.0 cm, P < 0.01)
and was similar to other reports [19]. Of these patients,
6 patients with metastasis had a biopsy performed, and
the others had an open adrenalectomy performed, in-
cluding 1 patient who chose follow-up for 2 years (with
tumour growth from 3 cm to 9 cm); therefore, operative
indications were critically important, and a new model
for preoperative evaluation might be a supplement to
the current guidelines [20].
However, for those patients with benign and nonfunc-
tioning tumours, adrenalectomy may be overutilised, es-
pecially in the era of laparoscopic adrenalectomy [3].
Vice versa, surveillance may miss some “silent” tumours
with the risk of being hypersecretory or malignant. It
was reported that conservative treatment led to a good
quality of life, and it was feasible [21]. In our hospital, a
conservative approach was presented for patients with
nonfunctioning tumours whose diameter was <4 cm and
had weak enhancement in imaging examination. How-
ever, likely over concern for malignant lesions or hormo-
nal transformation, in actuality, >50 % (470/634) of
patients preferred adrenalectomy to remove the tumour
and to confirm the pathology results. Of 332 patients
with nonfunctioning tumours with a size of ≤4 cm, 209
chose to have adrenalectomy, most of which were per-
formed in recent 5 years. Of 29 patients with a tumour
size >4 cm who chose surveillance, only 14 patients re-
fused operation, and the others had an unresectable sta-
tus. For different psychological and financial reasons, 6
patients with subclinical Cushing’s syndrome and 2 with
aldosteronism refused to have adrenalectomy. Psycho-
logically, patients were prone to adrenalectomy.
What’s more, delayed treatment might preclude the
opportunity for surgery when needed for ageing patients
with comorbidities. In this study, nearly half of patients
>55 years had to choose surveillance for poor functional
status. As popular as the laparoscopic technique is, this
minimally invasive approach has soon replaced trad-
itional adrenalectomy. For diagnostic efficiency of these
various adrenal tumours, surgeons tend to want to per-
form this new convenient operation, remove the tumour,
and obtain a pathological result. Moreover, a pathologic
result would possibly relieve the psychological and financial
burden. Additionally, recurrent evaluation with CT or hor-
monal examination and close follow-up might not be cost-
effective, though no economic analysis was performed. This
may play a role in increasing the need for adrenalectomy
now, more than in the era of open adrenalectomy. In recent
reports, several researchers demonstrated that patients with
adrenal incidentaloma were at risk of tumour growth
and hormonal transformation and might benefit from
adrenalectomy for reduced hypertension, cardiovascular
risk and other consequences [11–14, 22, 23]. In a study
with a long-term follow-up, cardiovascular events occurred
in 22 of 206 patients, and blood pressure control worsened
in 34 % patients. Interestingly, a tumour size >2.4 cm was
associated with patients developing subclinical hypercorti-
solism [22]. Therefore, adrenalectomy may be an option
for patients with small nonfunctioning adrenal incidenta-
loma, though it is debatable.
As a well-known medical centre in South China, se-
lective bias was considered as a limitation. Most patients
with huge adrenal tumours who transferred from other
hospitals had malignancy. Additionally, as a retrospective
analysis, patients were enrolled in the urological and
endocrine departments without a consistent management
protocol, which resulted in different evaluations.
Conclusions
Nonfunctioning adenoma is the most common tumour
of adrenal incidentaloma, and pheochromocytoma and
adrenocortical carcinoma were not rare. However, pre-
operative diagnosis is still undefined, and 4 cm is a good
cutoff for diagnosis. Laparoscopic adrenalectomy may
become a trend in the operative management of small
adrenal incidentaloma.
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